Silexion Therapeutics (NASDAQ:SLXN) Stock Price Down 0.4% – Here’s What Happened

Silexion Therapeutics Corp (NASDAQ:SLXN) shares traded down 0.4% on Wednesday . The company traded as low as $2.53 and last traded at $2.70. 92,192 shares changed hands during mid-day trading, a decline of 57% from the average session volume of 212,417 shares. The stock had previously closed at $2.71.

Analysts Set New Price Targets

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Silexion Therapeutics in a report on Monday, June 15th. One investment analyst has rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Silexion Therapeutics presently has an average rating of “Hold”.

Silexion Therapeutics Price Performance

The company’s 50-day simple moving average is $5.50 and its 200-day simple moving average is $14.14. The stock has a market capitalization of $1.13 million, a price-to-earnings ratio of -0.03 and a beta of -0.32.

Silexion Therapeutics (NASDAQ:SLXN) last posted its earnings results on Friday, May 15th. The company reported ($0.85) EPS for the quarter, beating the consensus estimate of ($12.90) by $12.05. Research analysts expect that Silexion Therapeutics Corp will post -45.5 earnings per share for the current year.

Silexion Therapeutics Company Profile

Silexion Therapeutics LTD, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical studies for the treatment of prostate cancer; and GBM-LODER that is in pre-clinical studies to target Glioblastoma Multiform, a malignant primary brain tumor.